全文获取类型
收费全文 | 1088篇 |
免费 | 50篇 |
国内免费 | 15篇 |
学科分类
医药卫生 | 1153篇 |
出版年
2021年 | 7篇 |
2020年 | 7篇 |
2019年 | 11篇 |
2018年 | 9篇 |
2017年 | 13篇 |
2016年 | 11篇 |
2015年 | 24篇 |
2014年 | 36篇 |
2013年 | 26篇 |
2012年 | 54篇 |
2011年 | 38篇 |
2010年 | 42篇 |
2009年 | 49篇 |
2008年 | 45篇 |
2007年 | 45篇 |
2006年 | 34篇 |
2005年 | 30篇 |
2004年 | 33篇 |
2003年 | 26篇 |
2002年 | 25篇 |
2001年 | 34篇 |
2000年 | 20篇 |
1999年 | 20篇 |
1998年 | 48篇 |
1997年 | 42篇 |
1996年 | 31篇 |
1995年 | 19篇 |
1994年 | 29篇 |
1993年 | 23篇 |
1992年 | 13篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 24篇 |
1988年 | 21篇 |
1987年 | 35篇 |
1986年 | 14篇 |
1985年 | 24篇 |
1984年 | 13篇 |
1983年 | 15篇 |
1982年 | 18篇 |
1981年 | 7篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 12篇 |
1977年 | 8篇 |
1976年 | 11篇 |
1975年 | 12篇 |
1974年 | 6篇 |
1968年 | 6篇 |
1967年 | 5篇 |
排序方式: 共有1153条查询结果,搜索用时 531 毫秒
11.
Murine sarcoma viruses: the helper-independence reported for a Moloney variant is unconfirmed; distinct strains differ in the size of their RNAs. 总被引:21,自引:0,他引:21
A variant of Moloney murine sarcoma virus (Mo-MSV) reported to behave like a nondefective sarcoma virus was subjected to biological and biochemical analyses to determine whether its alleged helper-independence could be confirmed. When plated at low multiplicity the virus was shown to readily generate (four out of six) transformed clones which failed to produce virus unless superinfected with helper leukemia virus. The RNA of the parental virus stock was compared electrophoretically to that from clones which produced virus after the initial infection (producer clones) or after superinfection with Mo-murine leukemia virus (MLV) (nonproducer clones). All clones contained a MSV-specific 30 S RNA species. In addition, virus from one producer clone also contained 38 S MLV RNA at a high relative concentration, indicating that the original Mo-MSV stock must have contained such an RNA species. However, the original virus stock as well as virus from another producer clone contained 38 S MLV RNA at a low, uncertain relative concentration. A hypothesis consistent with these and previous data suggests that the Mo-MSV variant investigated here is defective and contains helper leukemia virus at a low concentration. This explains (i) the ready generation of nonproducer clones by infection at low multiplicity, (ii) the difficulty in detecting helper leukemia virus 38 S RNA in the original virus stock, and (iii) the low complexity (approximately 1.9 × 106 daltons) of the MSV-specific 30 S RNA. These results are compatible with the properties reported for a defective MSV genome, but incompatible with those of a nondefective MSV genome. The MSV-specific RNA components of different clonal isolates of Mo-MSV differed from each other in size, ranging between 2.1 and 1.6 × 106. The Harvey sarcoma virus-specific RNA was 1.9 × 106, that of Kirsten sarcoma virus was 2.5 × 106, and the spleen focus forming component of Friend virus was 2.0 × 106. The sarcoma- or transformation-specific RNA components of all transforming viruses tested here were smaller than the 38 S RNA of helper leukemia viruses of 3.1 × 106. 相似文献
12.
Background
The current status of radioiodine-131 (RaI) dosimetry for Graves' hyperthyroidism is not clear. Recurrent hyperthyroidism and iatrogenic hypothyroidism are two problems which interact such that trying to solve one leads to exacerbation of the other. Optimized RaI therapy has therefore begun to be defined just in terms of early hypothyroidism (ablative therapy) as physicians have given up on reducing hypothyroidism.Methods
Optimized therapy is evaluated both in terms of the greatest separation of cure rate from hypothyroidism rate (non-ablative therapy) or in terms of early hypothyroidism (ablative therapy) by mathematical modeling of outcome after radioiodine and critically discussing the three common methods of RaI dosing for Graves' disease.Results
Cure follows a logarithmic relationship to activity administered or absorbed dose, while hypothyroidism follows a linear relationship. The effect of including or omitting factors in the calculation of the administered I–131 activity such as the measured thyroid uptake and effective half-life of RaI or giving extra compensation for gland size is discussed.Conclusions
Very little benefit can be gained by employing complicated methods of RaI dose selection for non-ablative therapy since the standard activity model shows the best potential for cure and prolonged euthyroidism. For ablative therapy, a standard MBq/g dosing provides the best outcome in terms of cure and early hypothyroidism. 相似文献13.
14.
Canfield MC; Tamarappoo BK; Moses AM; Verkman AS; Holtzman EJ 《Human molecular genetics》1997,6(11):1865-1871
Congenital nephrogenic diabetes insipidus (NDI) is a rare disease caused
most often by mutations in the vasopressin V2 receptor (AVPR2). We studied
a family which included a female patient with NDI with symptoms dating from
infancy. The patient responded to large doses of desmopressin (dDAVP) which
decreased urine volume from 10 to 4 I/day. Neither the parents nor the
three sisters were polyuric. The patient was found to be a compound
heterozygote for two novel recessive point mutations in the aquaporin-2
(AQP2) gene: L22V in exon 1 and C181W in exon 3. Residue Cys181 in AQP2 is
the site for inhibition of water permeation by mercurial compounds and is
located near to the NPA motif conserved in all aquaporins. Osmotic water
permeability (Pf) in Xenopus oocytes injected with cRNA encoding C181W-AQP2
was not increased over water control, while expression of L22V cRNA
increased the Pf to approximately 60% of that for wild-type AQP2.
Co-injection of the mutant cRNAs with the wild-type cRNA did not affect the
function of the wild-type AQP2. Immunolocalization of AQP2-transfected CHO
cells showed that the C181W mutant had an endoplasmic reticulum-like
intracellular distribution, whereas L22V and wild-type AQP2 showed endosome
and plasma membrane staining. Water permeability assays showed a high Pf in
cells expressing wild-type and L22V AQP2. This study indicates that AQP2
mutations can confer partially responsive NDI.
相似文献
15.
Reciprocal effect of Waardenburg syndrome mutations on DNA binding by the Pax-3 paired domain and homeodomain 总被引:1,自引:1,他引:1
The Pax-3 protein contains two DNA-binding domains, a paired domain and a
homeodomain. Mutations in Pax-3 cause Waardenburg syndrome (WS) in humans
and the mouse Splotch (Sp) phenotype. In the Sp-delayed mouse, a mutation
in the Pax-3 paired domain (G9R) abrogates the DNA-binding activity of both
the paired domain and the homeodomain, suggesting that they may
functionally interact. To investigate this possibility further, we have
analyzed the DNA-binding properties of additional point mutants in the
Pax-3 paired domain and homeodomain that occur in WS patients (F12L, N14H,
G15S, P17L, R23L, G48A, S51F and G66D in the paired domain, V47F and R53G
in the homeodomain), the Pax-1 un mutation (G15A) and a substitution
associated with Peters' anomaly in the PAX-6 gene (R23G). Within the paired
domain, seven of 10 mutations were found to abrogate DNA-binding by the
paired domain. Remarkably, these seven mutations also affected DNA binding
by the homeodomain, causing either a complete loss (P17L and G66D), a
reduction (R23G, R23L, G15S and G15A) or an increase in DNA-binding
activity (N14H). In addition, the effect of paired domain mutations
occurred at the level of monomer formation by the homeodomain, while the
dimerization potential of this domain seemed unaffected in mutants where it
could be analyzed. Furthermore, while both homeodomain mutations were found
to abolish DNA binding by this domain, the R53G mutation also abrogated DNA
binding by the paired domain. The important observation that independent
mutations in either domain can affect DNA binding by the other in the
intact Pax- 3 protein strongly suggests that the two domains are not
functionally independent but bind DNA through cooperative interactions.
Modeling the deleterlous mutations on the three-dimensional structure of
the paired domain of Drosophila Prd shows that these mutations cluster at
the DNA interface, thus suggesting that a series of DNA contacts are
essential for DNA binding by both the paired domain and the homeodomain of
Pax-3.
相似文献
16.
Maisel L 《Health progress (Saint Louis, Mo.)》1994,75(8):26-8, 41
It is not enough that a healthcare facility have a "crisis plan" somewhere in its file cabinets. Indeed, unless the facility's executives have made thorough preparations for putting it into action, their plan could make a crisis even worse. Shortcomings commonly found in crisis plans include: Failing to make sure that the people designated to implement the plan are actually present when a crisis occurs Having a crisis team that is too large and unwieldy to be effective in a real crisis Forgetting that, while the crisis team acts, others must keep normal operations running Failing to designate a single, trained spokesperson to deal with the media Being unprepared for a long siege-the crisis that goes on for hours, days, or even weeks Forgetting during a crisis to inform, not only the general public, but also one's own staff, patients, and others Failing to have an understanding with staff and their unions that, in a crisis, some persons may be expected to perform duties other than their normal ones 相似文献
17.
The prevalence of microalbuminuria was assessed in 50 patients of non-insulin dependent diabetes mellitus. The mean age of patients was 52.1 ± 11.6 years and the duration of diabetes was 8.3 ± 6.8 years. Twenty (40%) patients had microalbuminuria. Microalbuminuria was more common in patients with a longer duration of diabetes (more than 5 years), a poor glycaemic control, and higher systolic blood pressure.KEY WORDS: Microalbuminuria, Diabetes mellitus, Diabetic nephropathy, Chronic renal failure 相似文献
18.
AS Harvey 《Journal of paediatrics and child health》2003,39(8):640-640
19.
20.
WF Paterson E McNeill S Reid AS Hollman MD Donaldson 《Archives of disease in childhood》1998,79(4):323-327
OBJECTIVE: To assess the efficacy of a longer acting preparation of the gonadotrophin releasing hormone (GnRH) analogue goserelin (Zoladex LA, 10.8 mg) in 12 girls with central precocious or early puberty. METHODS: Two girls started treatment de novo; the remainder had been on suppressive treatment for a median duration of 1.5 (range, 0.2-5.6) years. Assessment comprising auxology, pubertal staging, and pelvic ultrasound examination was carried out at weeks 0, 4, 8, 10, and 12 (first cycle) and weeks 8, 10, and 12 (second cycle) to evaluate the required injection frequency. Thereafter, assessment was performed on the day of injection. Zoladex LA was given every 12 weeks unless pubertal progression occurred. RESULTS: Satisfactory control was achieved in eight patients using this regimen, and three patients required more frequent injections. One girl was removed from the study because of clinical progression and extreme mood swings. No serious adverse effects occurred. Mean height velocity during the study period was 4.5 cm/year (range, 3.1-6.6) compared with 6.5 cm/year (range, 3.8-9.6) before treatment in nine patients for whom data were available. CONCLUSIONS: Zoladex LA was effective in controlling precocious puberty in girls when given at intervals of 9-12 weeks and it is recommended that an initial assessment is made eight weeks after beginning treatment. 相似文献